Dengue Tetravalent Vaccine
The technology describes a novel recombinant envelop domain-III based tetravalent protein which elicits protective immune responses against each of the four serotypes of dengue virus, DEN-1, DEN-2, DEN-3 and DEN-4. Hence it is capable of inhibiting the infectivity of each dengue virus serotype which is responsible for different form of dengue fever. The technology further suggests a process for the preparation of this tetravalent protein which involves codon optimizing the sequence, followed by cloning, transforming and purifying the novel recombinant tetravalent protein. This technology has been tested on mice.
Sector: Pharmaceuticals
Country: India
Area of Application: Medical industry.
Keywords: Dengue, vaccination
Advantages: It is a tetravalent vaccine against four different serotypes of dengue virus i.e. DEN-1, DEN-2, DEN-3 and DEN-4. Effective against different types of dengue serotypes. It inhibits the infectivity of each dengue virus serotype. Cost effective option in comparison to existing treatments.
Environmental aspects: Not Applicable
Development Status: Laboratory Model
Legal Protection:  
Technical specifications:  
Transfer Terms: Technology Licensing
Target Countries:  
Estimated cost (US$):  
Upload any relevant document:  
Contact Person: SkyQuest Technology Consulting Pvt. Ltd.
Address: 501, Krishna Complex, Opp. Devashish School, Bodakdev
City: Ahmedabad
Country: India
Zip/Pin Code: 380054

Contact Technology Provider